OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

Last updated: July 7, 2023
Sponsor: University Hospital, Bordeaux
Overall Status: Active - Recruiting

Phase

N/A

Condition

Thrombocytopenia And Thrombocytopenia Prevention

Immune (Idiopathic) Thrombocytopenic Purpura (Itp)

Lupus

Treatment

data collection

Clinical Study ID

NCT05937828
CHUBX 2023/08
  • Ages < 17
  • All Genders

Study Summary

From 2004, OBS'CEREVANCE is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : Immune thrombocytopenia (ITP), Autoimmune Hemolytic anemia (AIHA), or Evans syndrome (all bi or tri cytopenias). Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de Référence National des Cytopénies Auto-Immunes de l'Enfant) missions for care, education and research. Specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of ITP, AIHA, Evans Syndrome
  • Onset before the age of 18

Exclusion

Exclusion Criteria:

  • Opposition of legal representative or to data collection

Study Design

Total Participants: 3500
Treatment Group(s): 1
Primary Treatment: data collection
Phase:
Study Start date:
September 01, 2010
Estimated Completion Date:
December 31, 2029

Study Description

Immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AHAI) are rare childhood diseases that involve autoimmune destruction of platelets and erythrocytes respectively.

They may be associated with an even rarer entity, Evans syndrome (ES). These three conditions are referred to as autoimmune cytopenias (AIC).

In association with CAI, patients may present with various immunopathological (IM) manifestations such as lymphoproliferation, autoimmune autoimmune/autoinflammatory organ diseases that may be absent at the time of at the time of diagnosis of CAI and develop during follow-up.

Since 2004, the CEREVANCE reference center for childhood autoimmune CEREVANCE has been coordinating a national prospective cohort of patients with pediatric-onset CAI including over 1900 patients (data 05/2023).

Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de Référence National des Cytopénies Auto-Immunes de l'Enfant) missions for care, education and research. Specifically, this original unbiased database allows to describe the long-term health of adult patients, to identify the heterogenous genetic underlying pathophysiologic contexts, and to study the benefit-risk balance of treatments, including the growing development of targeted therapies.

Connect with a study center

  • CHU Amiens Picardie Service d' Onco-Immuno-Hématologie Pédiatrique

    Amiens,
    France

    Active - Recruiting

  • CHU d'Angers Unité d'Hémato-Oncologie Pédiatrique

    Angers,
    France

    Active - Recruiting

  • BESANCON CHU de Besançon Hôpital Jean MINJOZ Unité d'Hémato-Oncologie Pédiatrique, Pédiatrie 1

    Besançon,
    France

    Active - Recruiting

  • CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique

    Bordeaux,
    France

    Active - Recruiting

  • CHU BREST Hôpital Morvan Unité d'Onco-Hématologie

    Brest,
    France

    Active - Recruiting

  • CHU de Caen Unité d'Onco-Hématologie

    Caen,
    France

    Active - Recruiting

  • CHU de Clermont Ferrand

    Clermont-Ferrand,
    France

    Active - Recruiting

  • APHP Hôpital Bicêtre Service de Pédiatrie générale

    Paris,
    France

    Active - Recruiting

  • CH de Cornouaille Service de Pédiatrie

    Quimper,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.